ArticlePloS one2026
Synthesis and evaluation of haemocompatible, antioxidant, and antibacterial properties, and acute oral toxicity of a methacrylic acid mediated glucoxylan for wound healing applications.
Article in PloS one, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
10 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Herein, a copolymeric hydrogel comprising a naturally occurring swellable biopolymer, i.e., glucoxylan (a major polysaccharide of chia seed mucilage (CM)) and methacrylic acid (MA), was synthesized through free radical polymerization for wound healing applications. The formation of CM-co-MA was authenticated through FTIR spectroscopy. The CM-co-MA appeared non-hemolytic and non-thrombogenic, and exhibited noteworthy antioxidant potential with DPPH scavenging activity ranging from 18.68 to 47.70 µg AAE µg/mL, FRAP activity from 32.22 to 63.70 µg AAE µg/mL, TFC from 27.91 to 73.59 µg QE/mL, and TPC from 26.95 to 58.21 µg GAE/mL. The CM-co-MA showed antibacterial activities against Listeria monocytogenes (Gram-positive) and Escherichia coli (Gram-negative), having a zone of inhibition (ZOI) of 27.87 and 23.00 mm, respectively. The antifungal activities were recorded against Aspergillus flavus and Candida albicans, and found the length of growth inhibition of 72 and 76 mm, respectively. The acute oral toxicity study, acute dermal toxicity, and eye irritation test demonstrated the non-toxic, innocuous, and non-irritant attributes of the CM-co-MA, respectively. All animals stayed alive without any significant abnormalities during the 14 day study, and all hematological and biochemical parameters of the control and experimental group animals were comparable. Histopathology of the vital organs of rabbits also showed normal cellular architecture without any abnormalities. A wound healing study on rabbits revealed the tissue regeneration, with 84.40% recovery in treated rabbits after 14 days, and comparable with the positive control. Hence, the CM-co-MA is considered a non-toxic material having haemocompatibility, antioxidant, antibacterial, and antifungal activities for potential application in wound healing.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.